Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype

(2020) Carminia M. Della Corte et al.   Journal of Thoracic Oncology

MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate

(2020) Abbie S. Ireland et al.   CANCER CELL

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

(2019) Triparna Sen et al.   Cancer Discovery

Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo

(2019) Brian H. White et al.   JOURNAL OF MEDICINAL CHEMISTRY

Immunotherapy for small cell lung cancer: mechanisms of resistance

(2019) Gerhard Hamilton et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Determining cell type abundance and expression from bulk tissues with digital cytometry

(2019) Aaron M. Newman et al.   NATURE BIOTECHNOLOGY

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer

(2019) Constantia Pantelidou et al.   Cancer Discovery

MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion

(2019) Milind D. Chalishazar et al.   CLINICAL CANCER RESEARCH

Tumor Heterogeneity Underlies Differential Cisplatin Sensitivity in Mouse Models of Small-Cell Lung Cancer

(2019) Franziska Böttger et al.   Cell Reports

Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer

(2019) Anna F. Farago et al.   Cancer Discovery

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

(2019) Taofeek K. Owonikoko et al.   Journal of Thoracic Oncology

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer

(2019) Kerry A. Whalen et al.   MOLECULAR CANCER THERAPEUTICS

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

(2019) Hyun Cheol Chung et al.   Journal of Thoracic Oncology

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

(2018) Matthew D. Hellmann et al.   CANCER CELL

POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer

(2018) Yu-Han Huang et al.   GENES & DEVELOPMENT

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

(2018) M. Catherine Pietanza et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrating single-cell transcriptomic data across different conditions, technologies, and species

(2018) Andrew Butler et al.   NATURE BIOTECHNOLOGY

Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses

(2018) Israel Cañadas et al.   NATURE MEDICINE

RNA velocity of single cells

(2018) Gioele La Manno et al.   NATURE

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

(2018) Patrick A. Ott et al.   JOURNAL OF CLINICAL ONCOLOGY

Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer

(2018) Shunsuke Kitajima et al.   Cancer Discovery

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer

(2017) Efrat Dotan et al.   JOURNAL OF CLINICAL ONCOLOGY

Labetuzumab govitecan in metastatic colorectal cancer

(2017) Manjulika Das   LANCET ONCOLOGY

Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)

(2017) Robert M. Sharkey et al.   MOLECULAR CANCER THERAPEUTICS

Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer

(2017) Jing Shan Lim et al.   NATURE

Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies

(2017) Robert J. Cardnell et al.   Oncotarget

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer

(2017) C. Allison Stewart et al.   Oncotarget

PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer

(2016) Benjamin H. Lok et al.   CLINICAL CANCER RESEARCH

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer

(2016) Eileen E. Parkes et al.   JNCI-Journal of the National Cancer Institute

Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression

(2016) Eric Polley et al.   JNCI-Journal of the National Cancer Institute

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

(2016) Scott J Antonia et al.   LANCET ONCOLOGY

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition

(2016) Junko Murai et al.   Oncotarget

ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs

(2016) Mark D. Borromeo et al.   Cell Reports

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer

(2016) Eileen E. Parkes et al.   JNCI-Journal of the National Cancer Institute

Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression

(2016) Eric Polley et al.   JNCI-Journal of the National Cancer Institute

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

(2015) M. P. Mak et al.   CLINICAL CANCER RESEARCH

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

Robust enumeration of cell subsets from tissue expression profiles

(2015) Aaron M Newman et al.   NATURE METHODS

Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

(2015) F. Skoulidis et al.   Cancer Discovery

Small cell lung cancer: Where do we go from here?

(2014) Lauren Averett Byers et al.   CANCER

Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer

(2014) Cassandra L Hodgkinson et al.   NATURE MEDICINE

Tumor Cell Heterogeneity in Small Cell Lung Cancer (SCLC): Phenotypical and Functional Differences Associated with Epithelial-Mesenchymal Transition (EMT) and DNA Methylation Changes

(2014) Alexander Krohn et al.   PLoS One

PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer

(2013) Teruyuki Sato et al.   Scientific Reports

Targeting MICA with therapeutic antibodies for the treatment of cancer

(2013) Cécile Bonnafous et al.   Journal for ImmunoTherapy of Cancer

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

(2012) C. M. Rudin et al.   CLINICAL CANCER RESEARCH

An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

(2012) L. A. Byers et al.   CLINICAL CANCER RESEARCH

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

(2012) Lauren Averett Byers et al.   Cancer Discovery

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer

(2011) Paul K. Paik et al.   LUNG CANCER